EPIDIOLEX® (cannabidiol)
The first and only FDA approved cannabidiol.
Information and resources for healthcare professionals.
For questions about scientific and clinical information regarding Greenwich Biosciences products, submit a medical request form or contact Medical Information by phone.
Explore pertinent response documents and publications for Greenwich Biosciences product(s).
The first and only FDA approved cannabidiol.
The links to these reprints are being provided for educational purposes only. The data reported in these publications may differ from or may not be included in the full Prescribing Information. See link to full prescribing information above. Prescription drugs used outside of their approved indications may not be eligible for reimbursement by third-party payers including Medicare, Medicaid or similar federal or state programs. Financial and conflict of interest disclosures are included within each respective publication.
For more information about cannabinoids, access the resources at the links below.
Find additional information for healthcare professionals, patients, and caregivers about epilepsy, Dravet syndrome, and Lennox-Gastaut syndrome.
View the Greenwich Biosciences Pipeline for information about medicines in development.
Access ClinicalTrials.gov for a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. It is a service of the US National Institutes of Health.
Greenwich Biosciences is proud to support continuing medical education for healthcare professionals, helping to ensure that their patients receive the highest quality of care.
Our primary areas of focus for educational support are cannabinoid science and disorders of the central nervous system, including epilepsy. This global program is open to physicians, researchers, and institutions interested in conducting external research.
Please send your requests to grants@greenwichbiosciences.com.
• A letter of request including the amount you are requesting
• A detailed proposal including a draft agenda, needs assessment, the target audience, number of participants anticipated, and accreditation (if applicable)
• Overall budget for the program
• Any additional information to aid in our review
This section contains helpful resources including videos, symposia, and downloadable educational materials about the science behind our mission.
Jacquelyn Bainbridge, PharmD, FCCP
Expires: August 23, 2022
Jacquelyn L. Bainbridge, PharmD, FCCP; Sheldon J. Rich, R.Ph., Ph.D.
Expires: November 21, 2020
Anup Patel, MD
Medscape website will ask you to log in, but registration is free.
Expires: December 19, 2020
Lawrence W. Brown, MD; Gregory D. Cascino, MD; Christina SanInocencio, MS
Medscape website will ask you to log in, but registration is free.
Expires: February 7, 2021
Anup D. Patel, MD
Medscape website will ask you to log in, but registration is free.
Expires: May 6, 2021
C. Michael White, Pharm D
Expires: May 15, 2021
Jacquelyn L. Bainbridge, PharmD, FCCP; Laura Borgelt, PharmD, MBA, FCCP, BCPS
Expires: May 20, 2021
Elizabeth A. Thiele, MD, PhD
Medscape website will ask you to log in, but registration is free.
Expires: May 29, 2021
Orrin Devinsky, MD
Medscape website will ask you to log in, but registration is free.
Expires: June 8, 2021
Tyler Elyse Gaston, MD; Anup Patel, MD
Medscape website will ask you to log in, but registration is free.
Expires: June 11, 2021
Daniel Friedman, MD, MSc; Anup D. Patel, MD
Medscape website will ask you to log in, but registration is free.
Expires: March 21, 2019
Ethan Russo, MD; Barry Gidal, PharmD
Medscape website will ask you to log in, but registration is free.
Expires: October 31, 2019
Jacquelyn L. Bainbridge, PharmD, FCCP
Expires: December 10, 2019
Tracy A. Glauser, MD; Orrin Devinsky, MD; Tracy Dixon Salazar, PhD; Anup D. Patel, MD; Elizabeth A. Thiele, MD, PhD
Medscape website will ask you to log in, but registration is free.
Expires: December 17, 2019
Participation in one of our clinical trials is the optimal way for patients to gain access to our investigational medicines. However, we understand that some patients may not be able to participate in a clinical trial and may seek access to investigational medicines before they are approved. For such patients, the FDA may authorize Expanded Access Programs (EAPs), also known as Compassionate Use Programs, to facilitate access to investigational drugs for the treatment of patients with a serious or immediately life-threatening disease or a condition which lacks therapeutic alternatives.
To obtain more information about Expanded Access, click here.
Greenwich Biosciences will consider granting expanded access to an investigational product only if all of the following criteria are met:
In addition to the criteria noted above, Greenwich Biosciences reserves the right to evaluate expanded access requests on additional criteria on a case-by-case basis.
You are leaving the website of Greenwich Biosciences, Inc., the US subsidiary of GW Pharmaceuticals plc. This link will take you to a website to which our Privacy Policy does not apply.
We are closely monitoring our supply chain of EPIDIOLEX® (cannabidiol) and, at this time, do not foresee any supply interruptions in the United States.
At Greenwich Biosciences, our main concern is the well-being of our patients, healthcare partners, and employees. Our hearts and thoughts go out to the people who have been affected. We are monitoring the COVID-19 situation and have taken steps to ensure that access and assistance for patients remain consistent.